 |
|
|
| |
SVR Results of Weight-based Taribavirin Versus Weight-based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients
|
| |
| |
Reported by Jules Levin
AASLD Nov 3 2009 Boston
F. Poordad1, E. Lawitz2, T. Hassanein3, M. Shiffman4, B. Bacon5,
A. Muir6, J. Heise7, D. Halliman7, E. Chun7, J. Hammond7
1Cedars-Sinai Medical Center, Los Angeles, CA, USA
2 Alamo Medical Research, San Antonio, TX, USA
3 SCTI Research Foundation Liver Center, San Clemente, CA, USA
4 Virginia Commonwealth University Medical Center, Richmond, VA, USA
5 St. Louis University School of Medicine, St. Louis, MO, USA
6 Duke University Medical Center, Durham, NC, USA
7 Valeant Pharmaceuticals North America, Aliso Viejo, CA, USA
This study was funded by Valeant Pharmaceuticals North America, Aliso Viejo, California
*Erythropoietic stimulating agents were not allowed
*anemia more severe in HIV/HCV and ESRD
1 M Sulkowski, E Lawitz, ML Shiffman, et al. Final results of the IDEAL Phase IIIb study. EASL 2008. Milan, Italy.
2 P Kwo, E Lawitz, J Mccone et al. HCV SPRINT-1 final results. EASL 2009. Copenhagen, Denmark.
3 P Kwo, E Lawitz, J Mccone et al. HCV SPRINT-1 Interim results. AASLD 2008. San Francisco, CA.
4 I Jacobson et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1infection (PROVE 1).
AASLD 2007.
|
| |
|
|
|
|
|
